Cancer Treatment Centers of America

We're available 24/7
(800) 615-3055

Chat online with us

Chat now

Other ways to contact us

Have us
call you
(800) 615-3055

Have questions? Call (800) 615-3055 to speak to a cancer information specialist.
Or we can call you.

TGen's Huentelman and Weiss named to 2013 Class of 40 Under 40

Newspaper recognizes TGen researchers among Phoenix’s brightest young leaders

PHOENIX, Ariz. — June 5, 2013 — Dr. Matt Huentelman of the Translational Genomics Research Institute (TGen) and Dr. Glen Weiss of TGen and Cancer Treatment Centers of America® (CTCA) are among the 40 business leaders under 40 years of age named by the Phoenix Business Journal to its 13th Annual Class of 40 Under 40.

They will be honored at an awards ceremony June 27 at the Phoenix Art Museum.

Dr. Huentelman, Ph.D., is an Associate Professor in TGen’s Neurogenomics Division, where he oversees research programs focused on sensory disorders, including hearing and vision loss, and on aging and age-related diseases, such as Alzheimer’s disease and the genetics of learning and memory — highlighted recently by the launch of TGen’s MindCrowd project (

Dr. Huentelman also is the Co-Director of TGen’s Center for Rare Childhood Disorders, which investigates uncommon neurologic problems among children, often those that are only a collection of symptoms with no diagnosis.

“I am honored to be selected among the 40 Under 40 by the Phoenix Business Journal,” Dr. Huentelman said. “This recognition serves to highlight the significant advances that TGen has made through the study of the human genome, and the insights and breakthroughs being made, not only by me, but by our entire scientific staff every day.”

Dr. Weiss, M.D., is a Clinical Associate Professor in TGen’s Cancer and Cell Biology Division and is Director of Clinical Research at CTCA®. His research focuses on genomic and other 'omics characterizations of lung cancer, rare cancers and early-detection strategies.

Dr. Weiss has been selected by CTCA at Western Regional Medical Center to head the startup of a new clinical research program in Goodyear, Ariz. Dr. Weiss is also Co-Unit Head of TGen’s Lung Cancer Research Laboratory.

“As a research scientist, being a member of the 40 Under 40 is a reflection of the collaborations I am privileged to conduct through TGen and CTCA,” Dr. Weiss said. “As a medical doctor, these collaborations lead to new therapies that can help the patients that look to us for healing and hope.”

The 40 Under 40 program’s hundreds of alumni includes Phoenix Mayor Greg Stanton, a member of the TGen Board of Directors, and Arizona Diamondbacks President Derrick Hall, a member of TGen's National Advisory Council for Pancreatic Cancer Research.

About Cancer Treatment Centers of America®
Cancer Treatment Centers of America® (CTCA), headquartered in Boca Raton, Fla., is a national network of five hospitals that serves adult patients who are fighting cancer. CTCA® offers an integrative approach to care that combines advancements in genomic testing and precision cancer treatment, surgery, radiation, immunotherapy and chemotherapy, with evidence-based complementary therapies that support patients physically and emotionally, enhancing their quality of life while reducing side effects both during and after treatment. CTCA serves patients from around the world at its hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Consistently rated among U.S. hospitals that deliver the highest quality of care and patient experience, CTCA provides patients and their families with comprehensive information about their treatment options and encourages their active participation in treatment decisions. For more information, visit, and

Cancer Types
Our Doctors